Skip to content
Back to search

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Nintedanib (ATC-Code: L01EX09) im Wege eines Open-House-Modells

AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPublished on Apr 02, 2026
292 days left

Description

The subject of this publication is the conclusion of non-exclusive agreements for medicines with the active substance Nintedanib (ATC Code: L01EX09). The contract conclusion takes place within the framework of a so-called Open-House model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This results in individual contract negotiations not being conducted and no (supply) exclusivity being given. It is pointed out that the procurement quantity is unknown, as this depends on demand and the development of the number of insured persons, the prescribing behaviour of doctors and the dispensing and stocking behaviour of public pharmacies. Accordingly, minimum procurement quantities are not guaranteed. Interested pharmaceutical companies can download the participation documents via the project room of the German Tender Portal (DTVP). To do this, an application for access to the project room is required. After the applicant has been released by the contracting authority, the participation documents can then be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents - in particular regarding the content of the agreement and the discounts mentioned therein. Any full or partial disclosure or making available of contents of the participation documents to or for third parties requires the prior written consent of the contracting authority. If participation is waived, all documents must be destroyed immediately in accordance with data protection regulations. The documents to be submitted result from the documents "Cover Letter" and "Explanations of the Contract Terms" stored in the project room. Communication, including the transmission of the participation documents, takes place electronically via the tender portal DTVP; details can be found in the aforementioned documents. Any contrary information in the contract notice is due to technical reasons and does not claim any binding effect. Participation applications can be submitted for the first time by 30 April 2026. All further submission deadlines can be found in the attachment "Submission Deadlines" stored in the project room. If the deadline for submission falls on a Saturday, Sunday or a nationwide public holiday, the next working day shall take the place of such a day. In the event of late receipt, the submitted participation applications will be considered for the next submission deadline. The agreement ends, regardless of the date of the contract conclusion, at the latest on 30 June 2027. The contracting authority reserves the right to terminate the Open-House procedure prematurely, in particular in the event of the conclusion of exclusive agreements; in this case, the agreements already concluded end in accordance with the contractual provisions. According to the experience of the contracting authority, exclusive agreements usually come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders